AC Immune–Hornstein J: management, 201701– CFO before Theo Müller Group + Merck KGaA

	Period	2017-01-01
	Successor	Lundbeck–Hornstein J: management, 202209– CFO before AC Immune + Theo Müller Group + Merck KGaA
	Organisation	AC Immune S.A. (Nasdaq: ACIU)
	Organisation 2	Merck KGaA
	Group	Merck (DE) (Group)
	Product	CNS drug (neurological drug)
	Product 2	crenezumab
	Person	Hornstein, Jörg (Lundbeck 202209– CFO before AC Immune + Theo Müller Group + Merck KGaA)

Record changed: 2022-04-08

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for AC Immune S.A. (Nasdaq: ACIU)

[1] H. Lundbeck A/S. (4/8/22). "Press Release: Joerg Hornstein to Join Lundbeck as Chief Financial Officer and Head of Corporate Functions". Valby....
[2] AC Immune S.A.. (12/19/18). "Press Release: AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership". Lausanne & Shanghai....
[3] AC Immune S.A.. (3/23/17). "Press Release: AC Immune Provides Twelve Update on Its Pipeline". Lausanne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]